Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, you can stop taking Wegovy at any time — it is not physically addictive, and there is no medically dangerous withdrawal syndrome. What does happen, for most people, is that appetite gradually returns and some of the weight lost during treatment comes back over the following weeks and months. The decision to stop is a real one, and it deserves an honest answer rather than a sales pitch. Wegovy (semaglutide 2.4mg) is a prescription-only medicine for weight management, so any plan to stop (or to carry on) should be discussed with the prescriber who oversees your treatment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide works by activating GLP-1 receptors involved in appetite regulation and the slowing of gastric emptying, which together reduce how hungry you feel and how quickly you want to eat again after a meal. When you stop taking it, those effects fade as the medicine clears your system. Because semaglutide has a roughly one-week half-life, the pharmacological effect diminishes gradually rather than overnight, but most people notice appetite returning within two to four weeks of their last dose.
There is no withdrawal in the clinical sense — no rebound anxiety, no physical dependence, no acute medical event linked purely to stopping. What people do experience is the return of the biological hunger signals that the medicine had been quietening. For some that feels manageable; for others it is a stark reminder of how much the medicine was doing. That honest realisation, shared by many patients who stop, is worth acknowledging: it is not a personal failing, it is pharmacology.
The full picture on stopping Wegovy is worth reading if you want the clinical detail on clearance timelines and what to monitor.
The evidence here is fairly consistent. The STEP 1 extension study followed participants who had completed 68 weeks of semaglutide 2.4mg treatment and then stopped. Within one year of stopping, participants regained, on average, about two-thirds of the weight they had lost during the active treatment phase. Cardiovascular risk markers also moved back towards pre-treatment levels over the same period. The STEP 1 trial, published in the New England Journal of Medicine, provides the underlying data that informs this picture.
That does not mean stopping is the wrong choice for everyone. Some people reach a weight that feels sustainable, have built robust lifestyle habits, and are ready to manage without medication. Others stop because of side effects, cost, or a change in health circumstances. The weight trajectory after stopping differs considerably between individuals depending on those lifestyle factors, so the average figure is a guide, not a prediction.
If you are weighing up cost as part of this decision, a Wegovy price comparison may help you see whether the specific number you are paying is typical for the UK private market.
The decision to stop is rarely just about the medicine itself. A few questions are worth thinking through before you do.
First: have you reached a weight that meaningfully reduces your health risk, or are you still partway through a treatment course? Stopping at a lower dose, before you have reached a maintenance phase, tends to produce less durable results. The question of when stopping is appropriate is one our prescribers hear regularly, and the answer is always individual.
Second: how established are the habits built during treatment? Appetite suppression from Wegovy can make it easier to reshape eating patterns. If those patterns are now genuinely automatic rather than effortful, they are more likely to persist after the medicine goes. If they still feel effortful, that is worth factoring in.
Third: why are you considering stopping? If it is side effects, there may be options (dose adjustment, timing changes, anti-nausea strategies) that your prescriber can explore before you stop entirely. The process of stopping Wegovy gradually is also an option some prescribers prefer over an abrupt end, though the evidence on tapering versus stopping cold is not conclusive.
The NHS guidance on weight management injections notes that lifestyle support remains central to outcomes regardless of how long medication continues, worth bearing in mind for whatever you decide.
Practically, stopping Wegovy is straightforward: you simply do not take your next weekly dose. There is no dangerous rebound, and you do not need to taper in most cases, though it is worth telling your prescriber before you stop rather than after. They can note it in your record and offer a follow-up plan if appropriate.
Weight regain, if it happens, tends to build gradually rather than returning all at once. Keeping the dietary and activity patterns from your treatment period in place is the most evidence-based buffer. This is also not an all-or-nothing moment: some people stop, monitor their weight over several months, and return to treatment if regain becomes significant. Stopping after reaching your goal weight has its own specific considerations.
There is also a broader question about what the right long-term plan looks like for you as an individual. Some people will benefit from indefinite treatment; others will not. The timeline for how Wegovy works gives useful context if you are trying to judge whether you have given the medicine a fair run before stopping.
If you are thinking about your options and want a clinical view rather than a general one, checking your eligibility for a consultation with one of our prescribers costs nothing and puts the decision in proper clinical context.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.